医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology

2019年04月24日 PM01:00
このエントリーをはてなブックマークに追加


 

SHANGHAI

EpimAb Biotherapeutics, an emerging biopharmaceutical company based in Shanghai, announced today that the United States Patent and Trademark Office (USPTO) has granted the U.S. Patent No. 10,266,608 entitled “Fabs-In-Tandem Immunoglobulin and Uses Thereof”. Based on EpimAb’s globally filed first application, this patent broadly covers bispecific antibodies obtained utilizing the company’s FIT-Ig® technology in a composition of matter claim.

“This patent underscores the novelty of EpimAb’s approach in bispecific antibody generation and forms an important foundation of EpimAb’s growing IP portfolio,” said Dr. Chengbin Wu, Founder and CEO of EpimAb Biotherapeutics. “The first granted patent in a major pharmaceutical market like the US therefore represents a significant milestone for EpimAb and takes us another step towards our goal to become a leading innovator in cancer biologics.”

EpimAb is developing multiple programs based on its FIT-Ig® platform for the treatment of various cancers. Its most advanced product candidate EMB-01, a cMet/EGFR bispecific with a novel mechanism of action was discovered and rapidly developed to the clinic by EpimAb. It is currently being investigated in a clinical Phase I/II trial in the USA and China. A second FIT-Ig molecule is currently under preclinical development with further molecules following soon, rapidly growing EpimAb’s pipeline of bispecific antibodies.

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties, without any mutations, peptide linkers, or non-Ig sequences. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. For further information, please visit www.epimab.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005880/en/

CONTACT

EpimAb Biotherapeutics
Dr. Stephan Lensky, COO/CBO
Direct:
+49 152 2610 7621
E-Mail: Stephan.lensky@epimab.com

Media Inquiries
Mario Brkulj or Amanda Houlihan
Direct:
+49 175 5711562 or +1 781 235 3060
E-Mail: epimab@macbiocom.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • エクセンシア、2022年第1四半期財務業績を2022年5月25日に報告
  • Anterra Capital:疫情和食品价格通胀激发了投资者对于加快食品和农业部门转型的兴趣
  • サーモの調査で、今年のASCOに参加するがん専門医が最も関心を寄せているのは肺がん・乳がんの新研究であることが判明
  • デンタル・モニタリングが包括的で生涯を通じた患者体験のための仮想診療プラットフォームを発表
  • Dental Monitoring推出虚拟诊疗平台,提供全方位的终身患者体验